Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases

被引:51
作者
Manevski, Nenad [2 ]
Kurkela, Mika [1 ]
Hoglund, Camilla [1 ]
Mauriala, Timo [1 ]
Court, Michael H. [3 ]
Yli-Kauhaluoma, Jari [2 ]
Finel, Moshe [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Ctr Drug Res, FI-00014 Helsinki, Finland
[2] Univ Helsinki, Fac Pharm, Div Pharmaceut Chem, FI-00014 Helsinki, Finland
[3] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
基金
芬兰科学院; 美国国家卫生研究院;
关键词
HUMAN LIVER-MICROSOMES; HUMAN URINE; UGT; HALLUCINOGENS; EXPRESSION; SUBSTRATE; 1A6; METABOLISM; STABILITY; KINETICS;
D O I
10.1124/dmd.109.031138
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have examined the glucuronidation of psilocin, a hallucinogenic indole alkaloid, by the 19 recombinant human UDP-glucuronosyltransferases (UGTs) of subfamilies 1A, 2A, and 2B. The glucuronidation of 4-hydroxyindole, a related indole that lacks the N,N-dimethylaminoethyl side chain, was studied as well. UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower. On the other hand, UGT1A6 was by far the most active enzyme mediating 4-hydroxyindole glucuronidation, whereas the activities of UGTs 1A7-1A10 toward 4-hydroxyindole resembled their respective psilocin glucuronidation rates. Psilocin glucuronidation by UGT1A10 followed Michaelis-Menten kinetics in which psilocin is a low-affinity high-turnover substrate (K-m = 3.8 mM; V-max = 2.5 nmol/min/mg). The kinetics of psilocin glucuronidation by UGT1A9 was more complex and may be best described by biphasic kinetics with both intermediate (K-m1 = 1.0 mM) and very low affinity components. The glucuronidation of 4-hydroxyindole by UGT1A6 exhibited higher affinity (K-m = 178 mu M) and strong substrate inhibition. Experiments with human liver and intestinal microsomes (HLM and HIM, respectively) revealed similar psilocin glucuronidation activity in both samples, but a much higher 4-hydroxyindole glucuronidation rate was found in HLM versus HIM. The expression levels of UGTs 1A6-1A10 in different tissues were studied by quantitative real-time-PCR, and the results, together with the activity assays findings, suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.
引用
收藏
页码:386 / 395
页数:10
相关论文
共 35 条
  • [1] Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography
    Anastos, N.
    Barnett, N. W.
    Pfeffer, F. M.
    Lewis, S. W.
    [J]. SCIENCE & JUSTICE, 2006, 46 (02) : 91 - 96
  • [2] Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials
    Bjornstad, Kristian
    Hulten, Peter
    Beck, Olof
    Helander, Anders
    [J]. CLINICAL TOXICOLOGY, 2009, 47 (06) : 566 - 572
  • [3] S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen
    Bowalgaha, K
    Elliot, DJ
    Mackenzie, PI
    Knights, KM
    Swedmark, S
    Miners, JO
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 423 - 433
  • [4] Glucuronidation of apomorphine
    El-Bachá, RS
    Leclerc, S
    Netter, P
    Magdalou, J
    Minn, A
    [J]. LIFE SCIENCES, 2000, 67 (14) : 1735 - 1745
  • [5] Fisher MB, 2000, DRUG METAB DISPOS, V28, P560
  • [6] Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
    Gonzalez-Maeso, Javier
    Weisstaub, Noelia V.
    Zhou, Mingming
    Chan, Pokman
    Ivic, Lidija
    Ang, Rosalind
    Lira, Alena
    Bradley-Moore, Maria
    Ge, Yongchao
    Zhou, Qiang
    Sealfon, Stuart C.
    Gingrich, Jay A.
    [J]. NEURON, 2007, 53 (03) : 439 - 452
  • [7] Grieshaber AF, 2001, J FORENSIC SCI, V46, P627
  • [8] Hallucinogens and dissociative agents naturally growing in the United States
    Halpern, JH
    [J]. PHARMACOLOGY & THERAPEUTICS, 2004, 102 (02) : 131 - 138
  • [9] Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man
    Hasler, F
    Bourquin, D
    Brenneisen, R
    Vollenweider, FX
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (02) : 331 - 339
  • [10] Hasler F, 1997, Pharm Acta Helv, V72, P175, DOI 10.1016/S0031-6865(97)00014-9